newsfilter
← Latest News
GlobeNewswire·

Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update

Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded Access Program